Search
Bismuth subcitrate potassium
go.drugbank.com/drugs/DB09275ApprovedInvestigationalA bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
Nomegestrol
go.drugbank.com/drugs/DB11636ApprovedNomegestrol is an ingredient in the EMA-authorised product Zoely.
Categories: Hormonal Contraceptives for Systemic UseOral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalStrains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with … The vaccine is created by weakening the wildtype before being placed into the oral vaccine.
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS.
Chlormidazole
go.drugbank.com/drugs/DB13611ExperimentalCategories: Antifungals for Topical Use, Antifungals for Dermatological UseSulfathiourea
go.drugbank.com/drugs/DB13699ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use1,2-dichlorobenzene
go.drugbank.com/drugs/DB13963ApprovedWithdrawnThis derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]
Ranpirnase
go.drugbank.com/drugs/DB04950InvestigationalIt is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.
Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].